Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Connect Biopharma Holdings ( (CNTB) ) just unveiled an update.
On July 22, 2025, Connect Biopharma Holdings Limited expanded its Board of Directors from six to seven members, appointing James A. Schoeneck as the new director. Mr. Schoeneck brings extensive experience from his previous roles as CEO of various pharmaceutical and biotechnology companies, including Depomed, Inc., BrainCells, Inc., and ActivX BioSciences, Inc. His appointment is expected to enhance the company’s strategic direction and governance, reflecting positively on its market positioning.
The most recent analyst rating on (CNTB) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.
Spark’s Take on CNTB Stock
According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.
Connect Biopharma Holdings’ overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.
To see Spark’s full report on CNTB stock, click here.
More about Connect Biopharma Holdings
Average Trading Volume: 118,848
Technical Sentiment Signal: Buy
Current Market Cap: $95.21M
See more insights into CNTB stock on TipRanks’ Stock Analysis page.